Related Experiment Video
Updated: Jul 4, 2025

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics
Published on: May 14, 2016
Weakened APC/C activity at mitotic exit drives cancer vulnerability to KIF18A inhibition
Colin R Gliech1, Zhong Y Yeow1, Daniel Tapias-Gomez1
1Department of Molecular Biology and Genetics, Johns Hopkins University School of Medicine, Baltimore, MD, 21205, USA.
Abstract:
The efficacy of current antimitotic cancer drugs is limited by toxicity in highly proliferative healthy tissues. A cancer-specific dependency on the microtubule motor protein KIF18A therefore makes it an attractive therapeutic target. Not all cancers require KIF18A, however, and the determinants underlying this distinction remain unclear. Here, we show that KIF18A inhibition drives a modest and widespread increase in spindle assembly checkpoint (SAC) signaling from kinetochores which can result in lethal mitotic delays. Whether cells arrest in mitosis depends on the robustness of the metaphase-to-anaphase transition, and cells predisposed with weak basal anaphase-promoting complex/cyclosome (APC/C) activity and/or persistent SAC signaling through metaphase are uniquely sensitive to KIF18A inhibition. KIF18A-dependent cancer cells exhibit hallmarks of this SAC:APC/C imbalance, including a long metaphase-to-anaphase transition, and slow mitosis overall. Together, our data reveal vulnerabilities in the cell division apparatus of cancer cells that can be exploited for therapeutic benefit.
Insights
Targeting KIF18A offers a new cancer therapy approach. Inhibiting this motor protein causes mitotic delays, making cancer cells with specific cell division weaknesses vulnerable to treatment.
Area of Science:
- Cell Biology
- Cancer Therapeutics
- Molecular Oncology
Background:
- Current antimitotic drugs face limitations due to toxicity in healthy tissues.
- KIF18A, a microtubule motor protein, is a potential cancer therapeutic target due to cancer-specific dependencies.
- The reasons for varying KIF18A requirement across different cancers are not fully understood.
Purpose of the Study:
- To investigate the impact of KIF18A inhibition on cancer cell division.
- To identify the cellular determinants of sensitivity to KIF18A inhibition.
- To explore KIF18A as a viable therapeutic target by understanding its role in mitotic regulation.
Main Methods:
- KIF18A inhibition was induced in cancer cells.
- Spindle assembly checkpoint (SAC) signaling dynamics were analyzed.
- The metaphase-to-anaphase transition and anaphase-promoting complex/cyclosome (APC/C) activity were assessed.
- Cellular vulnerabilities related to mitosis were characterized.
Main Results:
- KIF18A inhibition led to increased SAC signaling and mitotic delays.
- Cancer cells with weaker APC/C activity or persistent SAC signaling showed heightened sensitivity.
- KIF18A-dependent cancers displayed hallmarks of SAC:APC/C imbalance, including prolonged metaphase-anaphase transitions.
- Overall mitosis was slower in sensitive cancer cells.
Conclusions:
- KIF18A inhibition exploits vulnerabilities in the cancer cell division machinery.
- The interplay between SAC signaling and APC/C activity dictates sensitivity to KIF18A inhibition.
- This study reveals a therapeutic strategy targeting specific cell division defects in cancer.
More Related Videos
Related Concept Videos
Inhibition of Cdk Activity
Anaphase Promoting Complex
Separation of Sister Chromatids
At the onset of anaphase, separase, a proteolytic enzyme, is...
Abnormal Proliferation
DNA Damage can Stall the Cell Cycle
M-Cdk Drives Transition Into Mitosis
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...

